NKG2A (KLRC1)
NKG2A is the brake on NK cells and some killer T cells that is pressed by HLA-E, a molecule tumours raise to look like self. Monalizumab blocks it and is in phase 3 with durvalumab in lung cancer and with cetuximab in head and neck cancer. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
A C-type lectin-like inhibitory receptor; the CD94/NKG2A heterodimer reads HLA-E and signals through ITIMs.
- NK cells; intraepithelial and memory CD8 T-cell subsets (UniProt P26715)
- Non-small-cell lung cancer and head and neck cancer trials of monalizumab
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"NKG2A" OR ABSTRACT:"NKG2A" OR TITLE:"KLRC1" OR ABSTRACT:"KLRC1" OR TITLE:"NKG2-A" OR ABSTRACT:"NKG2-A" OR TITLE:"CD159a" OR ABSTRACT:"CD159a" OR TITLE:"killer cell lectin like receptor C1" OR ABSTRACT:"killer cell lectin like receptor C1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NKG2A (KLRC1), not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/klrc1.json. Licence CC BY-NC 4.0.